Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Viridian Therapeutics, Inc.\DE | d385972dex321.htm |
| EX-31.2 - EX-31.2 - Viridian Therapeutics, Inc.\DE | d385972dex312.htm |
| EX-31.1 - EX-31.1 - Viridian Therapeutics, Inc.\DE | d385972dex311.htm |
| 10-Q/A - 10-Q/A - Viridian Therapeutics, Inc.\DE | d385972d10qa.htm |
Exhibit 10.14
[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
| Research Subaward Agreement Amendment | ||||||||
| Pass-through Entity (PTE) | Subrecipient | |||||||
| PTE: Yale University
|
Subrecipient: Miragen Therapeutics, Inc.
| |||||||
|
Address: Office of Sponsored Projects 25 Science Park – 3rd Floor 150 Munson Street P.O. Box 208327 |
Address: 6200 Lookout Road | |||||||
| City, State, Zip+4 (Country): New Haven, CT 06520-8327
|
City, State, Zip+4 (Country): Boulder, CO 80301
| |||||||
| PTE Principal Investigator (PI): [*], MD
|
Subrecipient Principal Investigator (PI): Rusty Montgomery, MD | |||||||
| PTE Federal Award No: 4UH2HL123886-03 REVISED |
FAIN: UH2HL123886 | Federal Awarding Agency: National Heart, Lung, and Blood Institute | ||||||
|
Project Title: Mir-29 mimicry as a therapy for pulmonary fibrosis
| ||||||||
| Subaward Period of Performance: Start Date: 8/19/2016 End Date: 6/30/2017
|
Amount Funded This Action: [*]
|
Amendment No: 3 |
Subaward No: M15A12064 (A10747)
| |||||
| Effective Date of Amendment: 10/27/2016
|
FFATA Reporting: Y
| |||||||
|
Amendment(s) to Original Terms and Conditions This Amendment revises the above-referenced Research Subaward Agreement as follows: | ||||||||
|
• Subaward Period of Performance is extended through June 30, 2017.
• Budget Period is August 19, 2016 to June 30, 2017.
• Authorized Funding for Budget Period is [*].
• Pre-award is authorized for July 1, 2016 to August 18, 2016.
| ||||||||
| All other terms and conditions of this Subaward Agreement remain in full force and effect. | ||||||||
| By an Authorized Official of Pass-through Entity: | By an Authorized Official of Subrecipient: | |||||||
| /s/ Cheryl Magoveny | 2/22/17 |
/s/ Jason A. Leverone | 1/23/17 | |||||
| Name: Andrea Lozano Title: Award Manager
|
Date |
Name: Jason A. Leverone Title: CFO
|
Date | |||||